SPRWF ~ HUGE potential for medical marijuana in Canada
After receiving a patent approval, David's previous pharmaceutical company, Praxis Pharmaceuticals, received an equity investment from Rothschild Bioscience Unit, a division of the worldwide Rothschild Group.
If people see David's affiliation with the world-renowned Rothschild Group, but fail to see the potential trajectory of Supreme Pharmaceuticals, they'll never know a good investment when they see it.
Supreme Pharmaceuticals President and CEO David Stadnyk
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.